Tilray Brands (NASDAQ:TLRY) Director David Hopkinson Sells 33,556 Shares

Tilray Brands, Inc. (NASDAQ:TLRY) Director David Hopkinson sold 33,556 shares of the stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Tilray Brands Stock Performance

Shares of NASDAQ:TLRY traded up $0.98 on Wednesday, reaching $7.87. 28,693,623 shares of the company’s stock were exchanged, compared to its average volume of 3,936,211. Tilray Brands, Inc. has a twelve month low of $3.51 and a twelve month high of $23.20. The company has a fifty day moving average of $7.03 and a 200-day moving average of $9.54. The company has a market capitalization of $917.25 million, a price-to-earnings ratio of -0.58 and a beta of 2.00. The company has a current ratio of 2.79, a quick ratio of 1.66 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings results on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.The company had revenue of $206.73 million during the quarter, compared to the consensus estimate of $201.35 million. During the same quarter in the previous year, the business posted ($0.87) EPS. On average, research analysts predict that Tilray Brands, Inc. will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TLRY. Roth Mkm raised shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Thursday, April 2nd. Canaccord Genuity Group began coverage on Tilray Brands in a report on Tuesday, January 27th. They issued a “hold” rating on the stock. TD Cowen decreased their price target on Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tilray Brands currently has an average rating of “Hold” and a consensus target price of $11.50.

Institutional Investors Weigh In On Tilray Brands

A number of hedge funds and other institutional investors have recently bought and sold shares of TLRY. Pictet Asset Management Holding SA increased its holdings in Tilray Brands by 38.9% in the 1st quarter. Pictet Asset Management Holding SA now owns 18,387 shares of the company’s stock worth $119,000 after purchasing an additional 5,145 shares in the last quarter. Alpine Global Management LLC bought a new stake in shares of Tilray Brands during the fourth quarter worth about $169,000. Voloridge Investment Management LLC bought a new stake in shares of Tilray Brands during the fourth quarter worth about $824,000. Polymer Capital Management US LLC acquired a new position in shares of Tilray Brands in the fourth quarter valued at approximately $1,058,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Tilray Brands in the fourth quarter valued at approximately $126,000. Institutional investors own 9.35% of the company’s stock.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Analysts/technicals point to a recovery — Technical coverage says Tilray is showing an early reversal and breakout as U.S. cannabis rescheduling momentum builds, reinforcing a continuation of the rally. Tilray Brands (TLRY) Price Forecast: Cannabis Rescheduling Fuels Recovery
• Positive Sentiment: Political headlines fueling optimism — Coverage notes a renewed rally after President Trump urged the DOJ to quickly reclassify cannabis to Schedule III, boosting hopes for faster industry tailwinds and option-market bullish positioning. Tilray Stock Pops on New Trump-Driven Cannabis Hopes. Should You Chase the Rally?
• Positive Sentiment: Wall Street bullish note — Roth Capital’s Bill Kirk published a bullish outlook saying TLRY could rise >40% over 12 months based on three positive business developments, which can attract more buy-side interest. 1 Wall Street Analyst Says Tilray Stock Could Jump Over 40%. Should You Believe It?
• Positive Sentiment: Unusually heavy call buying — Traders bought ~45,077 call options today (about +89% vs normal daily call volume), signaling speculative bullish positioning that likely amplified the rally and implied volatility.
• Neutral Sentiment: Trading halt (LULD pause) — The stock experienced an exchange-imposed LULD pause around 11:49 AM due to rapid price movement; this is a volatility-control measure rather than a company-specific announcement.
• Negative Sentiment: Fundamental headwinds remain — Recent Q1 results showed an EPS miss and wide negative margins; analysts still model negative EPS for the year, so while headlines can drive short-term gains, underlying profitability issues could limit sustained upside.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.